Aberrant protein expression of Appl1, Sortilin and Syndecan-1 during the biological progression of prostate cancer.
Martini C, et al. Pathology. 2023 Feb;55(1):40-51.
Overview
This novel study demonstrated that Appl1, Sortilin and Syndecan-1 monoclonal antibodies developed against unique epitopes reliably inform on the prostate cancer biology by improving morphological interpretation and assist pathology assessment when used as an IHC panel of three biomarkers. This study shows the cancer grading of up to 40% of prostate samples could be modified when the biomarkers are used. The results suggest the incorporation of these biomarkers may improve the consistency of prostate cancer diagnosis.
Download Paper
Prediction of Prostate Cancer Biochemical and Clinical Recurrence Is Improved by IHC-Assisted Grading Using Appl1, Sortilin and Syndecan-1
Logan JM, et al., Cancers (Basel). 2023 Jun 16;15(12):3215.
Overview
IHC biomarker-assisted grading was used to evaluate 114 prostatectomy tissue samples and compared to routine histological diagnosis. The results from both assessments were correlated to the patients’ clinical outcomes. The biomarker technology appeared to be superior to routine approaches in predicting the patients’ recurrence outcomes.
Download Paper
Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread.
Sorvina A, et al., Pathology. 2023 Oct;55(6):792-799.
Overview
Intraductal carcinoma of the prostate (IDCP) is associated with late-stage prostate cancer. This study centred on the evaluation of IHC prostate cancer biomarker reagents in IDCP and provided evidence for utility of the biomarker antibodies in the diagnosis of prostate cancer.
Download Paper
Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer.
Martini C, et al., Virchows Arch. 2023 Sep 14.
Overview
This study assesses the IHC prostate cancer biomarkers to provide insights into the biological relationship between intraductal carcinoma of the prostate (IDCP), high-grade prostatic intraepithelial neoplasia (HGPIN), and atypical intraductal proliferations (AIP) and their relevance to current clinicopathological recommendations. This study shows that the biomarker panel may be used as a tool to overcome the diagnostic uncertainty surrounding AIP by supporting a definitive diagnosis of IDCP for such lesions displaying the same labelling pattern as cribriform IDCP.
Download Paper
Dynamic interplay between sortilin and syndecan-1 contributes to prostate cancer progression.
Lazniewska J, et al., Sci Rep. 2023 Aug 18;13(1):13489.
Overview
This study shows that there is a dynamic balance between sortilin and syndecan-1, that reports on the different metabolic phenotypes of prostate cancer. Sortilin regulates glucose metabolism and is upregulated by androgen, which also induces glucose uptake, while androgen deprivation leads to overexpression of syndecan-1 and increases its interactions with LPL and αVβ3 integrin to facilitate lipid metabolism and cancer aggression.
Download Paper